Sharon Merims

624 total citations
28 papers, 431 citations indexed

About

Sharon Merims is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Sharon Merims has authored 28 papers receiving a total of 431 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 16 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Sharon Merims's work include Immunotherapy and Immune Responses (12 papers), CAR-T cell therapy research (10 papers) and Immune Cell Function and Interaction (10 papers). Sharon Merims is often cited by papers focused on Immunotherapy and Immune Responses (12 papers), CAR-T cell therapy research (10 papers) and Immune Cell Function and Interaction (10 papers). Sharon Merims collaborates with scholars based in Israel, United States and Canada. Sharon Merims's co-authors include Michal Lotem, Tamar Peretz, Galit Eisenberg, Shoshana Frankenburg, Olga Drize, Arieh Ingber, Jonathan Cohen, Stephen Jay Frank, Arthur Machlenkin and Gal Markel and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and PLoS ONE.

In The Last Decade

Sharon Merims

27 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sharon Merims Israel 13 296 194 100 34 28 28 431
Korina G. Veenstra United States 6 317 1.1× 216 1.1× 139 1.4× 54 1.6× 16 0.6× 8 484
Ruth Asher United Kingdom 9 207 0.7× 163 0.8× 154 1.5× 19 0.6× 23 0.8× 17 414
Jelle J. Lindenberg Netherlands 11 262 0.9× 185 1.0× 98 1.0× 26 0.8× 12 0.4× 14 373
Cécile Déjou France 7 257 0.9× 180 0.9× 78 0.8× 11 0.3× 14 0.5× 9 415
Jaeyop Lee United States 9 506 1.7× 129 0.7× 127 1.3× 26 0.8× 10 0.4× 12 589
Zsuzsanna Kurgyis Germany 8 177 0.6× 189 1.0× 85 0.8× 24 0.7× 38 1.4× 12 342
Louise A. Jopling United Kingdom 11 316 1.1× 233 1.2× 87 0.9× 20 0.6× 23 0.8× 14 502
Miki Ando Japan 12 151 0.5× 233 1.2× 152 1.5× 40 1.2× 8 0.3× 65 453
Isabel Longo Spain 8 160 0.5× 203 1.0× 93 0.9× 22 0.6× 72 2.6× 12 382

Countries citing papers authored by Sharon Merims

Since Specialization
Citations

This map shows the geographic impact of Sharon Merims's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Merims with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Merims more than expected).

Fields of papers citing papers by Sharon Merims

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Merims. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Merims. The network helps show where Sharon Merims may publish in the future.

Co-authorship network of co-authors of Sharon Merims

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Merims. A scholar is included among the top collaborators of Sharon Merims based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Merims. Sharon Merims is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weinstein‐Fudim, Liza, Shoshana Frankenburg, Tamar Peretz, et al.. (2023). Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions. Science Translational Medicine. 15(699). eabo0684–eabo0684.
2.
Hajaj, Emma, Sharon Merims, Jonathan Cohen, et al.. (2021). Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions. Cancer Immunology Research. 9(6). 637–650. 14 indexed citations
3.
Lavie, David, et al.. (2021). Pityriasis rubra pilaris induced by PD‐1 inhibitor nivolumab. International Journal of Dermatology. 60(8). 1038–1039. 3 indexed citations
4.
Greenberger, Shoshana, Alexander Maly, Sharon Merims, et al.. (2020). Subcutaneous granuloma annulare mimicking dermatomyositis. Pediatric Dermatology. 37(4). 687–689. 3 indexed citations
5.
Hajaj, Emma, Shiri Klein, Sharon Merims, et al.. (2020). Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study. Frontiers in Oncology. 10. 70–70. 30 indexed citations
6.
Hajaj, Emma, Galit Eisenberg, Shiri Klein, et al.. (2020). SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint. eLife. 9. 26 indexed citations
7.
Hirshoren, Nir, Jonathan Cohen, Jeffrey M. Weinberger, et al.. (2020). Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. PLoS ONE. 15(4). e0231038–e0231038. 7 indexed citations
8.
Eisenberg, Galit, Emma Hajaj, Sharon Merims, et al.. (2018). Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo. Cancer Immunology Research. 6(2). 127–138. 19 indexed citations
9.
Filippou, Panagiota S., Dimitrios Korbakis, Antoninus Soosaipillai, et al.. (2018). Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. Clinical Chemistry and Laboratory Medicine (CCLM). 56(11). 1945–1953. 14 indexed citations
10.
Cohen, Jonathan, et al.. (2017). Adoptive Cell Therapy: Past, Present and Future. Immunotherapy. 9(2). 183–196. 32 indexed citations
11.
Eisenberg, Galit, Sharon Merims, Shoshana Frankenburg, et al.. (2015). Human T Cell Crosstalk Is Induced by Tumor Membrane Transfer. PLoS ONE. 10(2). e0118244–e0118244. 11 indexed citations
12.
Barak, Vivian, et al.. (2015). Assessing Response to New Treatments and Prognosis in Melanoma Patients, by the Biomarker S-100β.. PubMed. 35(12). 6755–60. 5 indexed citations
13.
Merims, Sharon, Xujian Li, Betty Joe, et al.. (2011). Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy. Leukemia. 25(9). 1415–1422. 49 indexed citations
14.
Lotem, Michal, Luna Kadouri, Sharon Merims, et al.. (2011). HLA‐B35 correlates with a favorable outcome following adjuvant administration of an HLA‐matched allogeneic melanoma vaccine. Tissue Antigens. 78(3). 203–207. 2 indexed citations
15.
Merims, Sharon, Pouneh Dokouhaki, Betty Joe, & Li Zhang. (2010). Human Vδ1-T cells regulate immune responses by targeting autologous immature dendritic cells. Human Immunology. 72(1). 32–36. 5 indexed citations
16.
Katz, Gil, Roi Gazit, Tal I. Arnon, et al.. (2004). MHC Class I-Independent Recognition of NK-Activating Receptor KIR2DS4. The Journal of Immunology. 173(3). 1819–1825. 81 indexed citations
17.
Lotem, Michal, Eitan Shiloni, Itzhak Pappo, et al.. (2004). Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. British Journal of Cancer. 90(4). 773–780. 24 indexed citations
18.
Ingber, Arieh & Sharon Merims. (2004). The validity of the Mathias criteria for establishing occupational causation and aggravation of contact dermatitis. Contact Dermatitis. 51(1). 9–12. 20 indexed citations
19.
Basketter, David A., et al.. (2001). INVESTIGATION OF THE THRESHOLD FOR ALLERGIC REACTIVITY TO CHROMIUM.. Dermatitis. 12(2). 125–125. 1 indexed citations
20.
Basketter, David A., et al.. (2001). INVESTIGATION OF THE THRESHOLD FOR ALLERGIC REACTIVITY TO CHROMIUM.. American Journal of Contact Dermatitis. 12(2). 125–125. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Korina G. Veenstra Breakdown of academic impact, for papers by Ruth Asher Breakdown of academic impact, for papers by Jelle J. Lindenberg Breakdown of academic impact, for papers by Cécile Déjou Breakdown of academic impact, for papers by Jaeyop Lee Breakdown of academic impact, for papers by Zsuzsanna Kurgyis Breakdown of academic impact, for papers by Louise A. Jopling Breakdown of academic impact, for papers by Miki Ando Breakdown of academic impact, for papers by Isabel Longo
Rankless by CCL
2026